ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Phase 1/2 Terminated NCT03287271

Condition	Ovarian Cancer
Phase	Phase 1/2
Sponsor	Michael McHale
Status	Terminated
Enrollment	8 participants
Interventions	VS-6063, Paclitaxel, Carboplatin
Start date	Feb 6, 2018
Completion date	Jul 30, 2023
Results posted	Jul 31, 2026

Summary

The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.

Dose-Limiting Toxicity

28 days · Participants

Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel	1 Participants
Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel	1 Participants

Objective Response Rate (ORR)

4 years · Participants

Defactinib (VS-6063) + Carboplatin/Paclitaxel	0 Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulo — Beth Israel Deaconess Medical Center
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, — M.D. Anderson Cancer Center
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Trea — National Cancer Institute (NCI)
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunother — National Cancer Institute (NCI)
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский